Journal of Antimicrobial Chemotherapy, Vol 39, 35-42, Copyright © 1997 by The British Society for Antimicrobial Chemotherapy
LM Dembry, PA Farrel, DR Orcutt, LA Gerrity and VT Andriole
A comparison of MICs of trovafloxacin (CP-99,219) determined by the
standard microdilution broth method versus the Etest was performed for
multiple strains of Gram-positive and Gram-negative bacteria. A comparison
was also made of the in-vitro activity of trovafloxacin versus
ciprofloxacin and ofloxacin. The MIC50 and MIC90 were determined by both
methods for each species tested. The Etest resulted in MICs one to two
dilutions higher than the microdilution broth method. Trovafloxacin was the
most active agent against Gram-positive organisms. Ciprofloxacin was the
most active agent against Citrobacter freundii, Proteus mirabilis, Proteus
vulgaris, Morganella morganii and Serratia marcescens, while trovafloxacin
had equal or greater activity compared with ciprofloxacin and ofloxacin
against the other Gram- negative organisms tested. Overall, ofloxacin was
the least active agent tested. In addition, the in-vitro activity of
trovafloxacin or ciprofloxacin in combination with ampicillin/sulbactam,
gentamicin or vancomycin was evaluated. The combination of trovafloxacin
and gentamicin was synergic against two of 20 Enterococcus faecium
isolates, the combination of trovafloxacin and ampicillin/sulbactam was
synergic against two of 24 Enterococcus faecalis isolates, and the
combination of ciprofloxacin and gentamicin was synergic against one of 25
Stenotrophomonas maltophilia isolates. All other antibiotic combinations
resulted in an additive or indifferent effect.
ORIGINAL ARTICLES
In-vitro activity of trovafloxacin against sensitive and resistant aerobic bacteria using the standard microdilution broth method and Etest
Yale University School of Medicine, New Haven, CT, USA. Dembry@gwpo.ynhh.com
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  I. S. Barequet, P. Denton, G. J. Osterhout, S. Tuli, and T. P. O'Brien Treatment of Experimental Bacterial Keratitis With Topical Trovafloxacin Arch Ophthalmol, January 1, 2004; 122(1): 65 - 69. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. J. V. Piddock, M. M. Johnson, and M. A. Webber Activity of faropenem and imipenem for ciprofloxacin-resistant bacteria J. Antimicrob. Chemother., September 1, 2003; 52(3): 500 - 502. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. L. Credito, M. R. Jacobs, and P. C. Appelbaum In vitro activity of faropenem compared with eight agents against fourteen Gram-positive and Gram-negative bacteria by time-kill J. Antimicrob. Chemother., June 1, 2003; 51(6): 1437 - 1439. [Full Text] [PDF]
|
|
|
|
|
|
I. Milazzo, G. Blandino, F. Caccamo, R. Musumeci, G. Nicoletti, and A. Speciale Faropenem, a new oral penem: antibacterial activity against selected anaerobic and fastidious periodontal isolates J. Antimicrob. Chemother., March 1, 2003; 51(3): 721 - 725. [Abstract] [Full Text] [PDF]
|
|